ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research, and care delivery issues unique to countries and settings with limited health care resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author. Credentialed media can access published articles on the ASCO Publications site using their ASCO.org login information.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.

Publishing April 19, 2024, 4:00 PM ET:

Laparosopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial (Original Report)
Robert Fichtinger, et al
Request article

Publishing April 18, 2024, 4:00 PM ET:

Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma (Original Report)
Smita Bhatia, et al
Request article

Assessing the Role of Inflammation in Oral Tongue Carcinogenesis (Editorial)
Ann Gillenwater, et al
Request article

Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer (Original Report)
Elizabeth Kantor, et al
Request article

Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer-Associated Germline Pathogenic Variants in Mexico (Original Report)
Cynthia Villarreal-Garza, et al
Request article

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses (Original Report)
Panagiotis Konstantinopoulos, et al
Request article

Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance (Original Report)
Ashley Ross, et al
Request article

Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project (Original Report)
Victoria Serelli-Lee, et al
Request article

Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression (Original Report)
Ji-Youn Han, et al
Request article

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group (Special Article)
Scott Laurie, et al
Request article

Publishing April 17, 2024, 4:00 PM ET:

Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma (Original Report)
Sue Yom, et al
Request article

Integration of Telemedicine Consultation Into a Tertiary Radiation Oncology Department: Predictors of Use, Treatment Yield, and Effects on Patient Population (Original Report)
Yasamin Sharifzadeh, et al
Request article

Published April 16, 2024, 4:00 PM ET:

Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting (Original Report)
Beenish Manzoor, et al
Request article

Prostate Cancer Survivorship and Global Health-Related Quality of Life (Editorial)
Edward Christopher Dee, et al
Request article

Published April 15, 2024, 4:00 PM ET:

Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma (Original Report)
Derk Klatte, et al
Request article

Genomic Considerations in the Treatment of Thyroid Carcinoma (Editorial)
Crystal Hattum, et al
Request article

Organizational Breast Cancer Data Mart: A Solution for Assessing Outcomes of Imaging and Treatment (Original Report)
Margarita Zuley, et al
Request article

Published April 12, 2024, 4:00 PM ET:

Design and Implementation of an Opt-Out, End-to-End, Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine (Original Report)
Joseph O. Jacobson, et al
Request article

Machine Learning–Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma (Original Report)
Rasmus Rask Kragh Jørgensen, et al
Request article

Published April 11, 2024, 4:00 PM ET:

Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children’s Oncology Group Study (Original Report)
Sarah Alexander, et al
Request article

Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease (Original Report)
Jonas Abrahamsson, et al
Request article

Shining a Light: Unveiling Cardiac Risks Using Positron Emission Tomography Imaging in Lung Cancer Radiotherapy (Editorial)
Tobias Finazzi, et al
Request article

Envisioning Academic Global Oncologists: Proposed Competencies for Global Oncology Training from the American Society of Clinical Oncology (ASCO) (Special Article)
Maria Bourlon, et al
Request article

Financial Hardship Among Women With Breast Cancer in Addis Ababa Ethiopia: A Comparative Cross-Sectional Study (Original Report)
Alem Gebremariam, et al
Request article

Real-World Challenges of Managing Diffuse Large B-Cell Lymphoma in a Developing Country (Original Report)
Raheel Iftikhar, et al
Request article

Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in HR+/HER2- Advanced Breast Cancer: The BrasiLEEira Study (Original Report)
Anna M. Buehler, et al
Request article

Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 (Original Report)
Jun Gong, et al
Request article

NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor (Original Report)
Cristina Antonescu, et al
Request article

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 (Original Report)
Jun Gong, et al
Request article

Recently published Journal articles are featured on the homepage of each ASCO Journal website. Credentialed media can directly access these articles using their Media HQ login information on the Journal website. You will only need to log in once to access content for all ASCO Journals:

To apply for ASCO media credentials or renew your credentials, visit ASCO’s Media Headquarters and click “Create Account” or log in with your existing account information. To request your username or reset your password, click “Need Help. After submitting the required documentation, you will receive an email notification once your media credentials are approved. Your access to Journal articles will be activated within one week of approval. As you await access, once you have received notification of approved media credentials, submit your requested articles to Journal Request to receive them by email. 

The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.